1.
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang, P, Wang, D, Zhao, Y, Ren, S, Gao, K, Ye, Z, Wang, S, Pan, CW, Zhu, Y, Yan, Y, et al
Nature medicine. 2017;(9):1055-1062
-
-
Free full text
-
Abstract
Bromodomain and extraterminal domain (BET) protein inhibitors are emerging as promising anticancer therapies. The gene encoding the E3 ubiquitin ligase substrate-binding adaptor speckle-type POZ protein (SPOP) is the most frequently mutated in primary prostate cancer. Here we demonstrate that wild-type SPOP binds to and induces ubiquitination and proteasomal degradation of BET proteins (BRD2, BRD3 and BRD4) by recognizing a degron motif common among them. In contrast, prostate cancer-associated SPOP mutants show impaired binding to BET proteins, resulting in decreased proteasomal degradation and accumulation of these proteins in prostate cancer cell lines and patient specimens and causing resistance to BET inhibitors. Transcriptome and BRD4 cistrome analyses reveal enhanced expression of the GTPase RAC1 and cholesterol-biosynthesis-associated genes together with activation of AKT-mTORC1 signaling as a consequence of BRD4 stabilization. Our data show that resistance to BET inhibitors in SPOP-mutant prostate cancer can be overcome by combination with AKT inhibitors and further support the evaluation of SPOP mutations as biomarkers to guide BET-inhibitor-oriented therapy in patients with prostate cancer.
2.
[Effect of IGF-1 on proliferation and differentiation of primary human embryonic myoblasts].
Cen, S, Zhang, J, Huang, F, Yang, Z, Xie, H
Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery. 2008;(1):84-7
Abstract
OBJECTIVE To investigate the effect of IGF-1 on the growth of primary human embryonic myoblasts. METHODS The method of incorporation of 3H-TdR was used to evaluate the ability of proliferation of myoblasts. The count per minute (CPM) values of myoblasts at different concentrations (1, 2, 4, 8, 16 and 32 ng/mL) of IGF-1 were measured, and dose-effect curves were drawn to choose the optional concentration of IGF-1 to promote the proliferation. Then the experimental group of myoblasts received the addition of the optional concentration of IGF-1 in the growth medium, the control group just received the growth medium. The flow cytometry was used to detect the cell cycle. The method of incorporation of 3H-TdR was used to measure the peak-CPM. The myotube fusion rate was measured in myoblasts withdifferent concentrations (0, 5, 10, 15, 20, 25 and 30 ng/mL) of IGF-1 in fusion medium, the dose-effect curves were also drawn, so as to decided the optional concentration of IGF-1 in stimulating differentiation. Fusion medium with optional concentration of IGF-1 was used in experimental group, and the control group just with fusion medium. The fusion rate of myotube and the synthesis of creatine kinase (CK) were detected in both groups. RESULTS The optional concentration of 5 ng/mL IGF-1 was chosen for stimulating proliferation. It was shown that the time of cell cycle of control was 96 hours, but that of the experimental group was reduced to 60 hours. The results of flow cytometry showed that the time of G1 phase, S phase and G2M phase was 70.03, 25.01 and 0.96 hours respectively in control group, and were 22.66, 16.47 and 20.87 hours respectively in experimental group. The time-CPM value curves showed that the peak-CPM emerged at 96 hours in control group and 48 hours in experimental group, whichwas in agreement with the results of the flow cytometry. The optional concentration stimulating proliferation was 20 ng/mL IGF-1. Compared with control, the quantity of CK was increased by 2,000 mU/mL and the fusion rate was elevated by 30% in experimental group. CONCLUSION The concentrations of 20 ng/mL IGF-1 can elevat obviously the fusion rate and the quantity of CK. IGF-1 can enhance the proliferation and differentiation of myoblasts via inducing the number of myoblasts at G1 phase and increasing the number of myoblasts at S and G2M phases.